Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL815637 | 0.96 | KMT2A (0.39) | KMT2AMEN1RAB9AL3MBTL1PDE4B | |
| SCHEMBL816194 | 0.88 | KMT2A (0.34) | KMT2AMEN1RAB9AL3MBTL1PDE4B | |
| SCHEMBL815857 | 0.87 | CYP3A4 (0.41) | KMT2AMEN1RAB9AL3MBTL1PDE4B | |
| SCHEMBL13135271 | 0.85 | KMT2A (0.38) | KMT2AMEN1RAB9AL3MBTL1PDE4B | |
| SCHEMBL5961798 | 0.82 | KMT2A (0.41) | KMT2AMEN1L3MBTL1POLBHTT | |
| SCHEMBL816183 | 0.82 | KMT2A (0.38) | KMT2AMEN1RAB9AL3MBTL1PDE4B | |
| SCHEMBL19678430 | 0.81 | KMT2A (0.42) | KMT2AMEN1RAB9AL3MBTL1PDE4B | |
| SCHEMBL13174793 | 0.80 | KMT2A (0.34) | KMT2AMEN1RAB9AL3MBTL1PDE4B | |
| SCHEMBL5961803 | 0.77 | KMT2A (0.44) | KMT2AMEN1L3MBTL1POLBHTT | |
| SCHEMBL9999753 | 0.75 | KMT2A (0.38) | KMT2AMEN1RAB9AL3MBTL1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475991-B2 | Polymerizable liquid crystal composition, polarized light-emitting coating material, novel naphtholactam derivative novel coumarin derivative, novel nile red derivative, and novel anthracene derivative | ADEKA CORPORATION (JP) | 2016-10-25 | — | — | US | disclosed |
| US-8663497-B2 | Liquid crystal composition comprising polymerizable compound, and liquid crystal display element using said liquid crystal composition | ADEKA CORPORATION (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20130334461-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE | ADEKA CORPORATION (JP) | 2013-12-19 | — | — | US | disclosed |
| US-8512597-B2 | Polymerizable optically active imide compound and polymerizable composition containing the compound | ADEKA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8283000-B2 | Liquid crystal composition containing polymerizable compound and liquid crystal display using the liquid crystal composition | ADEKA CORPORATION (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20120200794-A1 | LIQUID CRYSTAL COMPOSITION COMPRISING POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAID LIQUID CRYSTAL COMPOSITION | ADEKA CORPORATION (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8057701-B2 | Trifunctional (meth)acrylate compound and polymerizable composition containing same | ADEKA CORPORATION (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | ADEKA CORPORATION (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110037025-A1 | TRIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING SAME | ADEKA CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20100328601-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL DISPLAY USING THE LIQUID CRYSTAL COMPOSITION | ADEKA CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | H1-4, XPO4, F12 | KMT2A 3009/4885MEN1 264/4885RAB9A 3238/4885 |
| US-20110037025-A1 | TRIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING SAME | PYM1, MT-CO1, MAT1A | KMT2A 1215/4885MEN1 255/4885RAB9A 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.